Safety and tolerability of the bolus 5-fluorouracil (5-FU) based FLOX and IFL regimens in patients who developed fluoropyrimidine-induced coronary vasospasm during therapy with infusional 5-FU or capecitabine.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e15513-e15513
10.1200/jco.2018.36.15_suppl.e15513